| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8148401 | PFIZER | Benzimidazole derivatives |
Jan, 2031
(6 years from now) | |
| US10414748 | PFIZER | Crystalline forms of 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate |
Apr, 2036
(11 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8431597 | PFIZER | Benzimidazole derivatives |
Jun, 2028
(4 years from now) | |
| US11168066 | PFIZER | Crystalline forms of 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate |
Apr, 2036
(11 years from now) | |
Daurismo is owned by Pfizer.
Daurismo contains Glasdegib Maleate.
Daurismo has a total of 4 drug patents out of which 0 drug patents have expired.
Daurismo was authorised for market use on 21 November, 2018.
Daurismo is available in tablet;oral dosage forms.
Daurismo can be used as use, in combination with low-dose cytarabine, for the treatment of newly-diagnosed acute myeloid leukemia (aml) in adult patients who are >= 75 years old or who have comorbidities that preclude use of intensive induction chemotherapy.
Drug patent challenges can be filed against Daurismo from 21 November, 2022.
The generics of Daurismo are possible to be released after 13 April, 2036.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-224) | Nov 21, 2025 |
| New Chemical Entity Exclusivity(NCE) | Nov 21, 2023 |
Drugs and Companies using GLASDEGIB MALEATE ingredient
NCE-1 date: 21 November, 2022
Market Authorisation Date: 21 November, 2018
Treatment: Use, in combination with low-dose cytarabine, for the treatment of newly-diagnosed acute myeloid leukemia (aml) in adult patients who are >= 75 years old or who have comorbidities that preclude use of...
Dosage: TABLET;ORAL
DAURISMO family patents
